Estimated treatment differences between cohorts showed the semaglutide 2.4 mg cohort had significantly greater percentage ( 15.0%) and absolute reduction in weight ( 15.7 kg), greater reduction in BMI ( 4.2 kg/m 2 ), and significantly greater improvements in cardiometabolic risk factors, including SBP ( 6.7 mmHg), DBP ( 2.7 mmHg), HbA1c ( 0.5%), HDL-C (1.2 mg/dl), LDL-C ( 10.4 mg/dl), and triglycerides ( 34.3 mg/dl) at 12 months
Efficacy and safety of tirzepatide, a dual GIP and GLP-1 receptor agonist, in type 2 diabetes: a double-blind, randomised, phase 3 trial
Retatrutide is not a simple weight loss shortcut, and it should not be discussed with exaggerated claims
Using DHEA over a long period or at high doses may be associated with cancer, and short-term use at low doses may lead to side effects such as acne, insomnia, mood changes, headache, and stomach upset
For those who find these dietary adjustments insufficient, we can prescribe anti-nausea medication to help alleviate the discomfort
In addition to in situ effects on bone tissue, some natural or engineered EVs also participated in gut microecology in the anti-osteoporotic process, suggesting the involvement of the gutbone axis